TippingPoint Biosciences
June 23, 2026
5B
Type: Start-Up Stadium Session
Focus Area:
Oncology
TippingPoint Biosciences is building the first scalable platform to model disease-specific epigenetic states and systematically discover small molecules that selectively kill cells driven by inappropriate epigenetic cues. The company’s lead program targets Diffuse Midline Glioma (DIPG), a fatal pediatric brain cancer in which aberrant chromatin signaling globally rewires gene expression and creates unique therapeutic vulnerabilities.
Company HQ City:
San Francisco
Company HQ State:
CA
Company HQ Country:
United States
Year Founded:
2022
CEO
Laura Hsieh
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
){kind=logo}